In part 1 of this 3-part panel discussion filmed in Barcelona our panel of experts discuss the issue of outsourcing and what priorities need considering when making a purchasing decision.
In the final part of this 3-part panel discussion, our experts talk through the recent changes in the type of molecules and technologies the field are working with and what new technologies need to emerge to overcome current problems.
In our interview Chad talks about his career highlights, advice that he would share with his younger self about patience, and how his bioanalytical hero has helped in pushing him towards his goals.
Afshin Safavi, shares his perspective on the past, present and future of bioanalytical outsourcing (BioAgilytx)
Afshin Safavi, Founder and Global Chief Scientific Officer at BioAgilytix (NC, USA) shares his perspective on the past, present and future of bioanalytical outsourcing.
Business of bionanalysis: The impact of mergers, acquisitions, and organic growth on bioanalytical sciences
In this final video the Business of bioanalysis panelists discuss the impact of mergers, acquisitions, and organic growth on bioanalytical sciences. The scientific community in which we work goes beyond affiliation, movement of bioanalytical scientists and talent between CRO, pharmaceutical and instrument vendors. The business is robust, while management of corporate culture is critical.
In part 2 of the Business of Bioanalysis panel discussion 2017 our panelists discuss managing the pipeline of bioanalytical talent and staff, including recruiting, training and retaining key analytical experts. Universities are not the singular source generating talent in bioanalysis skill sets. Beyond compensation, continuous education, cross-training, job rotations, and customized recognition models, within the laboratory, are critical to enticing and retaining ‘the best’ in our CRO and pharmaceutical organizations.
In part 1 of this 3-part video filmed in Los Angeles (CA, USA) our panel of experts discuss investing in emerging bioanalytical technologies – when is too soon and when is too late? Acquisition of new tools to address unmet analytical needs requires practical considerations, such as platform reliability, scalability from discovery to the regulated environment and total cost of ownership.
Bioanalysis Zone and Bioanalysis attended the 11th WRIB meeting in Los Angeles (CA, USA) and had the opportunity to host a panel discussion with experts from leading pharmaceutical companies and CROs to discuss several contemporary topics including: emerging technologies; recurring and talent development; and mergers and acquisitions.
MilliporeSigma (Billerica, MA, USA) has announced the launch of their new Single Molecule Counting Platform that could aid drug discovery and development.
The authors demonstrate how the relationship between academia and not-for-profit organizations with large pharma and emerging biotech companies has shifted toward a more collaborative effort in bringing new therapies to the forefront.